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Abstract 
Introduction: Primary CVD as a result of increased venous hypertension caused mostly by reflux from valvular 
incompetence as an indication for venoactive drug treatment. The objective of the study was the association 
between three months of treatment with diosmin and changes to the angiogenic factors involved in the patho-
physiology and clinical symptoms of CVD.
Material and methods: 41 patients were included in the study. Plasma levels of tumour necrosis factor a 
(TNF-a), vascular endothelial growth factor (VEGF-A and VEGF-C), matrix metalloproteinase 9 (MMP-9), 
Cathepsine-L and endostatin were measured using an ELISA assay at baseline and after three months of dios-
min administration. Clinical evaluation was performed using duplex Doppler, the VAS scale, leg circumference 
measurement and BMI score. 
Results: Three-month treatment with diosmin was associated with a statistically significant decrease in TNF-a, 
VEGF-A, VEGF-C, MMP-9, Cathepsin-L and endostatin plasma levels with p < 0.01 and p < 0.05 respectively. 
The average ankle circumference decreased significantly from 30.45 (± 2.05) to 29.0 (± 1.43) (p < 0.05). 
Conclusion: Diosmin influence on the inflammatory and proteolytic mechanisms involved in the pathology of 
CVD, could modify endostatin release and angiogenic processes. 
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Introduction 
Pharmacological treatment of chronic venous dis-
ease (CVD) includes venoactive drugs that influence 
venous tone or capillary permeability and reduce 
leukocyte infiltration. Diosmin is a flavonoid that im-
proves lymphatic activity, microvascular permeability 
and microcirculatory flow by affecting the endothelium 
function and reducing oedema and inflammation [1]. 
Anti-inflammatory properties including inhibition of 
TNF-a, leukotriens synthesis and leukocyte activation/ 
/degranulation may increase microcirculatory blood 
flow and reduce oedema [2]. Some studies show signif-
icant changes in MMP expression and activity in relation 
to CVD caused by a prolonged increase to venous wall 
tension [3]. Immunohistochemical analyses of varicose 
vein tissue showed prominent localisation of MMP-9 
in the endothelial cells, intimal and adventitial layers of 
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varicose veins and such localisation is consistent with 
the role of MMP — degradation of extracellular matrix 
(ECM) proteins, collagen and elastin [4, 5]. The imbal-
ance in ECM protein degradation and increased plasma 
levels of MMPs correlated with d-dimers and elevated 
plasminogen activator inhibitor (PAI-1) suggesting 
a pro-thrombotic and pro-inflammatory state [6]. 
The prolonged pro-inflammatory state may result 
in changes to the endogenous angiogenic response 
through the release of pro-angiogenic (VEGF-A and 
VEGF-C) and anti-angiogenic agents i.e. endostatin as 
a cleavage fragment of collagen XVIII, a proteoglycan/ 
/collagen found in the vessel wall and basement mem-
branes [7–9]. Endostatin, a proteolytic fragment of 
the NC1 domain of collagen XVIII/proteoglycan, was 
identified as an endogenous angiogenesis inhibitor first 
isolated from the conditioned media of non-metastatic 
murine haemangioendothelioma cell lines EOMA [10]. 
As proteolytic activity is present in the CVD mechanism 
and endostatin is a collagen XVIII cleavage product it 
seemed to be justified to elucidate its role in the mech-
anisms involved in this pathology.
 Following this premise, we hypothesized that 
circulating endostatin plays a role in CVD pathophys-
iology and its plasma level may respond to prolonged 
administration of diosmin. 
Material and methods 
Patients 
Forty-one patients (20 men and 21 women, mean 
age 41 years) were enrolled in the study. Participants 
gave their informed consent before enrolment. Lo-
cal ethics committee approval was obtained (KE – 
0254/341/2015). Medical history was taken and clinical 
examination was performed for all patients. Clinically, 
and then echographically (Doppler ultrasound Toshiba 
Aplio, 5 MHz linear probe) diagnosed chronic venous 
disease was evaluated [11]. ABI was assessed in each 
patient. Inclusion criteria were as follows: Bilateral 
greater saphenous vein (GSV) insufficiency detailed 
CEAP [12] classification stage C2, C3 and C4, and not 
using venoactive drugs 30 days before inclusion in the 
trial. None of the patients in the trial used graduated 
compression stockings. All participants stated that using 
them was unbearable. Patients received 2 × 600 mg/ 
/day of diosmin (Phlebodia, Laboratoires Innothera, 
Arcueil, France). They were instructed not to change 
their daily habits. 
Exclusion criteria
Exclusion factors were as follows: age < 18 years, 
pregnancy, smoking, diabetes mellitus, chronic renal 
failure, liver and cardiac failure, diuretics medication, 
chronic infections, previous vein surgery, previous and 
present vein thrombosis, arterial and venous aneurysm, 
congenital vascular malformations, psoriasis, autoim-
mune disease and cancer. 
Laboratory procedures
Blood samples were collected between 8:00 hr 
and 10:00 hr always after overnight fasting. EDTA 
tubes were used to collect the blood; plasma samples 
obtained were centrifuged at 1500 × g for 10 min and 
stored in a freezer (–200C) until use. Total TNF-a, 
VEGF-C (Thermo Fisher, USA), VEGF-A (PromoCell 
GmbH, Germany), MMP-9, Cathepsin-L and Endosta-
tin (Elabscience, USA) levels were determined in 
duplicate by commercially available enzyme-linked 
immunosorbent assay (ELISA) and the mean value of 
both determinations was used. The procedures were 
performed strictly to manufacturer instructions. 
Leg circumferences, BMI and pain assessment
Leg circumferences were taken 13 cm from the 
floor in a standing position [13]. The procedure was 
done separately by two independent observers in the 
same temperature conditions and at the same time of 
day — 10:00 am. The result presented was the mean 
of the two leg measurements. BMI was calculated as 
weight/height2 (kg/m2). Pain level was assessed using 
the visual analogue scale (VAS) which went from 0 (no 
pain) to 10 cm (intolerable pain). 
Each study participant was consulted every 30 days 
during the study period. Laboratory procedures, leg 
circumferences, pain and BMI were assessed twice — 
at baseline (T0) and at day 90 (T3m). 
Statistical analysis 
Statistical analysis of the results (Statistica 10 soft-
ware, StatSoft Polska) was carried out using descriptive 
statistics and the following parameters: group size (N), 
arithmetic mean, median, minimum and maximum var-
iables and standard deviation (SD). The study groups 
were compared using the Kruskal-Wallis multiple com-
parison test. Correlation analyses were performed using 
the Spearman’s test. 
Results 
The clinical characteristics of the patients are sum-
marised in Table 1. 
Clinical symptoms 
The estimation of clinical symptoms allowed the 
division of the patients with CVI into particular classes: 
C2 — varicose vein; C3 — varicose vein and oedema; 
C4 — varicose vein, oedema and skin changes. Initially, 
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ultrasound examination (echo-Doppler assay) was used 
to assess blood flow changes in superficial and deep 
veins during the compression manoeuvre in standing 
position [11]. Bilateral GSV insufficiency with reflux 
longer than 1 sec. was assessed in 41 (100%) patients.
After three months of treatment with diosmin, no 
changes were noted in the echo-Doppler examinations, 
there were no episodes of thrombophlebitis or throm-
boembolism. B-mode echography showed a decrease of 
subcutaneous lymph in seven C3 and three C4 patients. 
There was a statistically significant decrease in the 
average leg circumference of patients (p < 0.05) from 
30.45 (± 2.05) to 29.0 (± 1.43) so the reduction in leg 
circumference was 4.6% in comparison T0 vs. T3m.
Pain, assessed on the VAS scale, was absent in 12 
(29.2%) participants of our study. The other patients 
reported minor pain ranging from 1 to 3 on the VAS 
scale and after three months of diosmin administration, 
19 patients reported less severe pain. The differences 
in reported pain levels at T0 vs T3m among the C2, C3 
and C4 groups were statistically insignificant.
Basic blood parameters 
Blood parameters were monitored at T0 and after 
three months of diosmin treatment to assess possible 
changes or abnormalities. The results are summarized 
in Table 2. The values obtained for each patient were 
within the acceptable range and no statistically significant 
changes (p < 0.05) in the level of the investigated factors 
were observed in patients after treatment with diosmin.
Monitoring levels of TNF-a, VEGF-A  
and VEGF-C 
There was a statistically significant decrease of aver-
age plasma levels of TNF-a, VEGF-C, and VEGF-A after 
diosmin therapy of p < 0.01 and p < 0.05, respectively. 
The results are listed in Table 3 and shown on Figure 1. 
Monitoring levels of MMP-9, Cathepsin-L  
and Endostatin 
There was a statistically significant decrease in the 
average plasma levels of MMP-9 and cathepsin-L after 
three months of diosmin treatment of p < 0.05 and 
a statistically significant (p < 0.05) decrease of plasma 
endostatin at T3m in comparison to baseline was found 
as presented in Table 4 and Figure 2. 
Analysis of data from C2, C3 and C4 CEAP
 Analysing the data from individual classifications of 
CVD patients, no statistically significant differences in 
levels of TNF-a, VFGF-A, VEGF-C, MMP-9, cathepsin-L 
and endostatin among C2, C3 and C4 patients were 
noted before and after diosmin treatment. 
Table. 1. Patient demographics at baseline (T0)
N 41
Age 39.73 ± 8.25
Male/ Female 20/21
BMI 25.95 (± 1.62)
CEAP C2 14
 C3 16
 C4 11
GSV reflux 41 (100%)
ABI 1.1 ± (0.11)
Dyslipidaemia 1 (2.43%)
Hypertension 2 (4.87%)
Statins 1 (2.43%)
Betablockers 2 (4.87%) 
Table 2. The average value (± SD) of selected physiological 
parameters in patients before (T0) and after three months of 
treatment (T3m) with diosmin
Parameter T0 T3m
Leukocytes [K/μL] 4.78 (± 0.5) 5.67 (± 0.6)
Total cholesterol  
[mmol/l]
4.1 (± 1.1) 4.4 (± 0.6.)
Triglycerides [mmol/] 1.6 (± 0.4) 1.7 (± 0.3)
CRP [mg/dl] 3.9 (± 0,91) 3.4 (± 0.88)
Complement C3  
[mmol/l]
1.56 (± 0.4) 1.63 (± 0.48)
Complement C4  
[mmol/l]
0.53 (± 0.63) 0.49 (± 0.15)
Fibrinogen [mg/dl] 318.4 (± 82.9) 331 (± 90.8)
D-dimer [μg/l] 414.9 (± 128.8) 378.5 (± 100.5)
INR 0.93(± 0.12) 0.97(± 0.15)
Creatinine [μmol/l] 82 (± 2.7) 89 (± 3.2)
Albumin [g/dl] 4.65 (± 1.76) 4.87 (± 0.81)
Sodium [mmol/l] 140.27 (± 1.24) 138.10 (± 1.38)
BMI 25.95 (± 1.62) 25.85 (± 1.72)
Table 3. The mean level (± SD) of TNF-a, VEGF-A and 
VEGF-C in plasma before and after three months of treat-
ment with diosmin
TNF-a 
(pg/ml)
VEGF-A 
(pg/ml)
VEGF-C 
(pg/ml)
T0 1087.79 (± 384.9) 88.3 (± 103.4) 527.18 (± 143.4)
T3m 408.0 (± 151.8)** 48.06 (± 19.2)*  370.1 (± 66.8)*
Note: *p < 0.05, ** p < 0.001
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Correlations analyses
Correlation analyses performed using the Spear-
man’s test (p < 0.05, s < 0.05) revealed statistically 
significant positive correlation between: 
 — endostatin T3m and MMP-9 at T3m (r = 0.33), 
 — MMP-9 T3m and cathepsin-L at T3m (r = 0.44). 
Moreover, a negative correlation between endosta-
tin T0 and VEGF-C T0 (r = –0.38) was noted (Fig. 3). 
There was a notable opposite correlation between 
endostatin and VEGF-C after three months of treatment 
with diosmin but without significance (r = 0.03).
Discussion 
In the present study, a significant association was 
found between plasma levels of endostatin, a fragment 
of vascular basement membrane collagen, and the 
inflammatory state corrected by prolonged diosmin 
administration. In our study, the highest levels of fac-
Figure 1. Plasma levels of TNF-a, VEGF-A, VEGF-C, before (T0) and after three months (T3m) of diosmin treatment
Figure 2. Plasma levels of endostatin (A), MMP-9 (B), and cathepsin-L (C) at baseline (T0) and after three months (T3m) of diosmin 
treatment
Figure 3. A. Positive correlation between endostatin and MMP-9 plasma levels at T3m. B. Positive correlation between MMP-9 
and cathepsin-L plasma level at T3m. C. Negative correlation between VEGF-C and endostatin plasma levels at T0
Table 4. The mean content (± SD) of MMP-9, Cathepsin-L 
and endostatin in plasma before and after three months of 
treatment with diosmin
MMP-9 
(ng/ml)
Cathepsin-L  
(ng/ml)
Endostatin 
(pg/ml)
T0 77.83 (± 17.7) 3.44 (± 0.81) 102.08 (± 24.4)
T3m 67.93 (± 15.1)* 2.66 (± 1.0)*  84.4± (14.0)*
Note: *p < 0.05
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tors regulating angiogenesis — endostatin and VEGFs 
peptides — were seen in the plasma of patients before 
diosmin treatment. 
The imbalance of vasoactive substances may con-
tribute to relaxation and remodelling of varicose veins. 
Due to venous dilatation and valvular incompetence 
blood flow in varicose veins is disrupted, resulting in 
the blood stasis and reflux observed in all patients in 
our study. After three months of diosmin treatment, 
a significant reduction of leg circumferences was ob-
served as a result of oedema regression.
However, the decrease in pain reported after three 
months of diosmin treatment was not statistically 
significant. Currently available venoactive drugs can 
attenuate various features of the inflammatory cascade, 
particularly the leukocyte-endothelium interactions 
leading to proteases release/activation and microvas-
cular hyperpermeability causing leg oedema associated 
with clinical symptoms in patients affected by CVD [7]. 
 Besides vascular inflammation and remodelling, the 
endothelium can regulate venous tone and microvas-
cular permeability through the release of inflammatory 
mediators. In our study, the increased plasma level of 
TNF-α, VEGF-A and VEGF-C at baseline correlates with 
the leg oedema objectively defined by leg circumference. 
As proangiogenic substances, VEGFs have a stimulatory 
effect on endothelial cells, inducing their proliferation 
and promoting base membrane/endothelium complex 
permeability resulting in increased oedema. Angiogen-
esis is initiated by cytokines such as fibroblast growth 
factor (FGF) and VEGF but in later stages, this process 
becomes dependent on platelet-derived growth factors 
(PDGF) and transforming growth factor-1 (TGF-1) [10, 
14]. Inducers of angiogenesis bind to the cell surface of 
heparan sulphate proteoglycans. VEGF requires pro-
teoglycans as cofactors in order to induce angiogenic 
signalling. Collagen XVIII is a core protein of heparan 
sulphate proteoglycan in vascular and epithelial base-
ment membranes so in this context the physiological 
role of collagen XVIII in relation to endothelial cells 
may be a positive cofactor for angiogenesis [15]. On 
the other hand, during angiogenesis, endothelial cells 
and monocytes release proteolytic enzymes, MMPs 
and cathepsin-L which cleave peptide bonds within 
the NC1 domain of collagen XVIII and then endostatin 
is released in order to become a local angiogenesis in-
hibitor. The collagen/endostatin system may have been 
considered a sensor of proteolytic activities related to 
angiogenesis and serve as a negative control through 
the release of anti-angiogenic fragments [10, 16]. 
In our study, the decrease of endostatin levels corre-
lated positively with MMP-9 and cathepsin-L plasma 
levels at the end of the study (T3m) which may confirm 
diminished proteolysis due to diosmin activity. This 
kind of activity may also modify the abovementioned 
interactions between VEGF and vascular basement 
membrane proteoglycans. 
The association between plasma proteolytic activ-
ity and endostatin levels confirmed that venous wall 
remodelling plays an active role in the mechanisms 
involved in CVD pathophysiology. ECM degradation 
is likely to contribute to the weakening and dilatation 
of veins. Disruption of the elastic fibres including frag-
mentation of elastic laminas and collagen fibres was 
observed in varicose veins and the total elastin content 
in varicose vein wall is decreased in comparison with 
non-varicose veins [17]. Loss of elastin and type III 
collagen correlates negatively with vein diameter meas-
ured by ultrasonography at rest and during the Valsalva 
manoeuvre and this alteration in the balance of elastin 
and collagen content may contribute to varicose vein 
wall weakening [17, 18]. 
ECM is a dynamic structure that maintains the 
integrity of the vein through interaction with cellular 
and extra-cellular components: the endothelium, the 
basic membrane, proteins, smooth muscle cells and 
fibroblasts. The development of CVD is characterised 
by inflammation, ECM degradation, proteolytic ac-
tivity and oedema. Several different types of proteo-
lytic enzymes such as cathepsins (-L, -K) and matrix 
metalloproteinases (MMP-9 and -2) are involved in 
venous wall remodelling processes but in collagen 
XVIII, proteolysis MMP-9 and cathepsin-L activity 
were described [4, 19]. 
 As mentioned, in our study the higher levels of 
MMP-9 were noted at baseline and decreased after 
three months of diosmin treatment. The nature of this 
mechanism is unknown because the regulation of MMP 
is complex and occurs at different levels, including gene 
transcription, protein translation, pro-MMP activation 
and endogenous inhibition by plasma proteins such 
as tissue inhibitors of metalloproteinase (TIMPs) and 
α-2-macroglobulin [20]. Circulating concentration of 
endostatin has been reported to rise in other diseases 
including inflammatory bowel disease and preeclampsia.
To the authors’ knowledge, there is currently no as-
sociation reported between plasma levels of endostatin 
and CVD pathophysiology in the literature. Elevated 
levels of type XVIII collagen/endostatin have been asso-
ciated with ischemic heart disease and stroke and have 
been linked to obesity and diabetes [8, 14]. In a study 
by Mitsuma et al. [16] the level of serum endostatin was 
inversely related to the extent of coronary collaterals 
suggesting that endostatin may play a role in collaterals 
formation. In contrast, Iribarren et al. [21] observed an 
elevated risk of myocardial infarction in patients with 
lower serum endostatin levels. In the study by Holsti 
et al. [22], a significant association was found between 
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the plasma levels of fragments from type IV collagen, 
collagen XVIII/endostatin as vascular membrane proteins 
and infrarenal aorta diameter. The highest level of these 
vascular basement membrane fragments was seen in the 
group with an established abdominal aortic aneurysm. 
The levels of type IV and XVIII collagen/endostatin were 
significantly and independently associated with the aortic 
diameter group, after adjusting for risk factors — diabe-
tes, hypertension and current smokers. As patients with 
diabetes and current smokers were not included in our 
study, we could not draw conclusions in that regard.
There is no current consensus on the role of circu-
lating endostatin in vascular disease but some authors 
support the hypothesis that circulating endostatin may 
be a marker of impaired collateral formation and re-
duced angiogenesis. Some studies showed significantly 
higher levels of serum VEGF and endostatin in patients 
at more advanced stages of heart failure. The concen-
tration of pro-inflammatory and angiogenic factors i.e. 
interleukin-6, fibroblast growth factor (FGF) and en-
dostatin were significantly associated with the presence 
of coronary collaterals and their formation is associated 
with the activation of pro-inflammatory factors and 
endostatin [15, 22, 23]. In order to elucidate the role 
of endostatin in CVD pathophysiology, an investigation 
into areas of other angiogenic cytokines such as IL-6, 
RANTES or Angiopietin-1, appears necessary. 
The study was limited by the small number of pa-
tients included but in fact the study cohort recruited 
was highly homogenous and all patients remain in ob-
servation until the end of the study. Our findings need 
to be confirmed in a larger study group and compared 
with more severe diseases (C5 and C6 CEAP) and 
healthy controls.
Conclusions 
To conclude, diosmin may influence the proteolysis 
mechanisms involved in ECM and basic membrane 
degradation which was expressed in our study by the 
decreased MMP-9, cathepsin-L and endostatin plasma 
levels. Elevated plasma levels of endostatin can be 
perceived as a marker of venous basement membrane 
degeneration and vein wall remodelling, which was pre-
viously demonstrated in the different abovementioned 
vascular diseases. 
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